title: Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion--a matched-pairs analysis.
abstract: OBJECTIVE
  Our aim was to evaluate differences in the outcome of bevacizumab or triamcinolone acetate (TA) treatment in patients with macular edema (ME) after central retinal vein occlusion (CRVO).
  
  
  METHODS
  In a retrospective assessment 9 bevacizumab-treated patients and 9 TA-treated ones with ME after CRVO were pair-matched according to initial best-corrected visual acuity (BCVA) and central macular thickness (CMT) as measured by Stratus optical coherence tomography. BCVA and CMT were the main endpoints.
  
  
  RESULTS
  The initial BCVA of 0.15 +/- 0.1 increased not significantly by 1.0 +/- 3.1 lines in the bevacizumab-treated patients after a mean of 10 months. The initial BCVA of 0.17 +/- 0.1 decreased by -1.0 +/- 5.2 lines after a mean of 13 months following initial TA injection. The only significant decrease in mean CMT by 239 +/- 209 microm occurred 8 weeks after initial bevacizumab injection.
  
  
  CONCLUSIONS
  Both substances are able to stabilize CMT and BCVA in ME after CRVO, but only bevacizumab was devoid of unfavorable intraocular pressure elevation.
authors.affiliation: Department of Ophthalmology, University of Würzburg, Würzburg, Germany. r.guthoff@uni-wuerzburg.de
authors.forename: Rainer
authors.initials: R
authors.lastname: Guthoff
authors.forename: Thomas
authors.initials: T
authors.lastname: Meigen
authors.forename: Kathrin
authors.initials: K
authors.lastname: Hennemann
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schrader
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D012160:Retina / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide